Erythrocin Lactobionate Side Effects

Generic name: erythromycin

Medically reviewed by Drugs.com. Last updated on Jul 16, 2024.

Note: This document provides detailed information about Erythrocin Lactobionate Side Effects associated with erythromycin. Some dosage forms listed on this page may not apply specifically to the brand name Erythrocin Lactobionate.

Applies to erythromycin: intravenous powder for solution.

Other dosage forms:

• oral capsule delayed release, oral powder for suspension, oral tablet, oral tablet delayed release, oral tablet enteric coated
• capsule, powder for suspension, suspension, tablet, tablet chewable

Precautions

It is very important that your doctor check you or your child's progress closely while you are receiving this medicine to make sure this medicine is working properly and to check for any unwanted effects.

If your or your child's symptoms do not improve within a few weeks, or if they become worse, check with your doctor.

You should not receive this medicine if you are also using astemizole (Hismanal®), cisapride (Propulsid®), dihydroergotamine (Migranal®), ergotamine (Ergomar®), pimozide (Orap®), terfenadine (Seldane®), or statin medicine (eg, lovastatin, simvastatin, Mevacor®, Zocor®). Using these medicines together may cause serious unwanted effects.

Check with your doctor right away if you or your child have pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, unusual tiredness or weakness, or yellow eyes or skin. These could be symptoms of a serious liver problem.

Erythromycin may cause diarrhea, and in some cases it can be severe. It may occur 2 months or more after you stop receiving this medicine. Do not take any medicine to treat diarrhea without first checking with your doctor. Diarrhea medicines may make the diarrhea worse or make it last longer. If you have any questions about this or if mild diarrhea continues or gets worse, check with your doctor.

This medicine can cause changes in heart rhythms, such as a condition called QT prolongation. It may change the way your heart beats and cause fainting or serious side effects in some patients. Contact your doctor right away if you or your child have any symptoms of heart rhythm problems, such as fast, pounding, or uneven heartbeat.

Infantile hypertrophic pyloric stenosis (IHPS) occurs in infants receiving this medicine. Tell your child's doctor right away if your child is vomiting or irritable during feeding.

Before you have any medical tests, tell the medical doctor in charge that you or your child are receiving this medicine. The results of some tests may be affected by this medicine.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Serious side effects

Along with its needed effects, erythromycin (the active ingredient contained in Erythrocin Lactobionate) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking erythromycin:

Other side effects

Some side effects of erythromycin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to erythromycin: compounding powder, injectable powder for injection, oral capsule, oral delayed release capsule, oral delayed release tablet, oral granule for reconstitution, oral suspension, oral tablet, oral tablet chewable, oral tablet coated particles.

General adverse events

The most commonly reported side effect included localized irritation, abdominal cramping, abdominal discomfort, and decreased appetite.^[Ref]

Gastrointestinal

• Common (1% to 10%): Abdominal cramping, abdominal pain, diarrhea, flatulence, infantile hypertrophic pyloric stenosis, nausea, severe non¬-bilious vomiting, soft defecation, vomiting
• Uncommon (0.1% to 1%): Abdominal discomfort, oral candidiasis
• Rare (0.01% to 0.1%): Pancreatitis, pseudomembranous colitis
• Very rare (less than 0.01%): Spastic hypertrophic pyloric stenosis (in children)^[Ref]

Abdominal pain, diarrhea, nausea, and vomiting may occur with treatment, and appear to be dose-related.

In a study with 157 infants given oral formations for pertussis prophylaxis, 7 (approximately 5%) developed irritability with feeding and severe, non-bilious vomiting associated with IHPS.

Pseudomembranous colitis may occur during or after treatment.^[Ref]

Metabolic

• Common (1% to 10%): Anorexia, decreased appetite^[Ref]

Anorexia may occur with treatment, and appears to be dose-related.^[Ref]

Cardiovascular

• Common (1% to 10%): Thrombophlebitis
• Uncommon (0.1% to 1%): Chest pain, palpitations
• Rare (0.01% to 0.1%): Atypical ventricular tachycardia, palpitations, QT interval prolongation/QT prolongation, torsade de pointes, ventricular arrhythmias/fatal ventricular arrhythmias
• Very rare (less than 0.01%): Cardiac arrhythmias
• Frequency not reported: Cardiac rhythmic disorders, hypotension, ventricular tachyarrhythmias, ventricular tachycardia^[Ref]

Local

• Common (1% to 10%): Local irritation
• Uncommon (0.1% to 1%): Venous irritation
• Rare (0.01% to 0.1%): Pain, vessel trauma^[Ref]

Slow infusion of diluted parenteral formulations (continuously or intermittently via IV over no less than 20 to 60 minutes) may alleviate venous trauma and pain.^[Ref]

Musculoskeletal

• Common (1% to 10%): Muscle spasms
• Rare (0.01% to 0.1%): Joint swelling, rhabdomyolysis
• Very rare (less than 0.01%): Myasthenia gravis unmasking, myasthenia gravis worsening^[Ref]

Psychiatric

• Common (1% to 10%): Irritability with feeding
• Rare (0.01% to 0.1%): Neonatal irritability
• Frequency not reported: Confusion, confusional state, hallucinations^[Ref]

Dermatologic

• Uncommon (0.1% to 1%): Erythema, exanthema, mild rash, pruritus, urticaria, urticarial exanthema
• Rare (0.01% to 0.1%): Erythema multiforme, mild skin eruptions, skin reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis
• Frequency not reported: Acute generalized exanthematous pustulosis (AGEP), bullous fixed eruptions, eczema, rashes with/without pruritus, skin eruptions, upper abdominal discomfort^[Ref]

Hepatic

• Uncommon (0.1% to 1%): Alkaline phosphatase elevations, ALT elevations, AST elevations, elevation of liver enzymes, GGT elevations
• Rare (0.01% to 0.1%): Cholestasis, cholestatic jaundice
• Very rare (less than 0.01%): Abnormal liver function test results, hepatitis, hepatomegaly, liver dysfunction with/without jaundice, liver failure
• Frequency not reported: Cholestatic hepatitis, hepatocellular hepatitis, jaundice, liver dysfunction^[Ref]

Abnormal liver function test results, hepatitis, and/or liver dysfunction may occur with oral formulations.^[Ref]

Immunologic

• Uncommon (0.1% to 1%): Overgrowth of nonsusceptible bacteria, overgrowth of nonsusceptible fungi^[Ref]

Hypersensitivity

• Uncommon (0.1% to 1%): Hypersensitivity
• Rare (0.01% to 0.1%): Allergic edema, allergic reactions, anaphylactic reaction, anaphylactic shock, anaphylaxis, angioedema
• Frequency not reported: Serious allergic reactions^[Ref]

Other

• Uncommon (0.1% to 1%): Reversible hearing loss
• Rare (0.01% to 0.1%): Pyrexia
• Very rare (less than 0.01%): Deafness, reversible deafness, tinnitus
• Frequency not reported: Discomfort, fever, malaise^[Ref]

Reversible hearing loss was more frequently reported in patients with renal or liver dysfunction.

Older patients, especially those with liver and/or renal dysfunction, may be at higher risk of developing increased risk of hearing loss, especially when given doses of at least 4 grams/day.^[Ref]

Genitourinary

• Uncommon (0.1% to 1%): Vaginal candidiasis^[Ref]

Endocrine

• Uncommon (0.1% to 1%): Lactate dehydrogenase (LDH) elevations^[Ref]

Nervous system

• Rare (0.01% to 0.1%): Central nervous system (CNS) damage, convulsions, seizures
• Frequency not reported: Dizziness, headache, mitochondrial optic neuropathy, somnolence, transient CNS side effects, vertigo^[Ref]

Renal

• Rare (0.01% to 0.1%): Damage to the kidneys
• Very rare (less than 0.01%): Tubulointerstitial nephritis
• Frequency not reported: Interstitial nephritis^[Ref]

Hematologic

• Rare (0.01% to 0.1%): Damage to the blood
• Frequency not reported: Eosinophilia^[Ref]

Ocular

• Frequency not reported: Blurred vision, diplopia, visual impairment^[Ref]

Respiratory

• Frequency not reported: Asthmatic states, dyspnea^[Ref]

See also:

Frequently asked questions

• What causes black hairy tongue?
• What are enteric-coated tablets?
• Can you take antibiotics while pregnant?

Further information

Erythrocin Lactobionate side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer